Show simple item record

dc.contributor.authorSmyth, LM
dc.contributor.authorTamura, K
dc.contributor.authorOliveira, M
dc.contributor.authorCiruelos, EM
dc.contributor.authorMayer, IA
dc.contributor.authorSablin, MP
dc.contributor.authorBiganzoli, L
dc.contributor.authorAmbrose, HJ
dc.contributor.authorAshton, Jack
dc.contributor.authorBarnicle, A
dc.contributor.authorCashell, DD
dc.contributor.authorCorcoran, C
dc.contributor.authorde Bruin, EC
dc.contributor.authorFoxley, A
dc.contributor.authorHauser, J
dc.contributor.authorLindemann, JPO
dc.contributor.authorMaudsley, R
dc.contributor.authorMcEwen, R
dc.contributor.authorMoschetta, M
dc.contributor.authorPass, M
dc.contributor.authorRowlands, V
dc.contributor.authorSchiavon, G
dc.contributor.authorBanerji, U
dc.contributor.authorScaltriti, M
dc.contributor.authorTaylor, BS
dc.contributor.authorChandarlapaty, S
dc.contributor.authorBaselga, J
dc.contributor.authorHyman, DM
dc.date.accessioned2020-06-15T12:57:43Z
dc.date.available2020-06-15T12:57:43Z
dc.date.issued2020en
dc.identifier.citationSmyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020.en
dc.identifier.pmid32312891en
dc.identifier.doi10.1158/1078-0432.ccr-19-3953en
dc.identifier.urihttp://hdl.handle.net/10541/622995
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1158/1078-0432.ccr-19-3953en
dc.titleCapivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast canceren
dc.typeArticleen
dc.contributor.departmentMedicine, Memorial Sloan Kettering Cancer Centeren
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record